<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROLENSA- bromfenac sodium solution/ drops </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PROLENSA™ (bromfenac ophthalmic solution) 0.07% safely and effectively.  See full prescribing information for PROLENSA™ ophthalmic solution.<br>PROLENSA™ (bromfenac ophthalmic solution) 0.07% <br>Initial U.S. Approval: 1997</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">PROLENSA is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery. (<a href="#i4i_indications_id_de595b1a-5cc0-49a7-8dd2-23decaddc00f">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. (<a href="#i4i_dosage_admin_duplicate_id_6013d032-ced5-4ffa-b925-62119c327b90">2.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Topical ophthalmic solution: bromfenac 0.07% (<a href="#i4i_dosage_form_strength_id_7fe169aa-0959-4652-8be5-6ec1b5bfc63d">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#i4i_contraindications_id_0b0c2372-bf11-4435-afb9-ac3b8abcbda1">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">• Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.1</a>) </p>
<p class="Highlighta">• Slow or Delayed Healing (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.2</a>) </p>
<p class="Highlighta">• Potential for cross-sensitivity (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.3</a>) </p>
<p class="Highlighta">• Increase <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.4</a>) </p>
<p class="Highlighta">• Corneal effects including <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.5</a>) </p>
<p class="Highlighta">• Contact Lens Wear (<a href="#i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf">5.6</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>. (<a href="#i4i_adverse_effects_duplicate_id_f8f4952f-d803-45de-b71b-cb90bcd66db3">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated at 1-800-323-0000, or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Use with Other Topical Ophthalmic Medications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Slow or Delayed Healing</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Potential for Cross-Sensitivity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Contact Lens Wear</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Slowed or Delayed Healing</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_de595b1a-5cc0-49a7-8dd2-23decaddc00f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">PROLENSA™ (bromfenac ophthalmic solution) 0.07% is indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5eb48697-4ef6-4d98-80c2-f2b631479ae6"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_6013d032-ced5-4ffa-b925-62119c327b90"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing</h2>
<p class="First">One drop of PROLENSA ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_duplicate_id_826ae0f8-206b-4993-ad92-06675c5d07b4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Use with Other Topical Ophthalmic Medications</h2>
<p class="First">PROLENSA ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_7fe169aa-0959-4652-8be5-6ec1b5bfc63d"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Topical ophthalmic solution: bromfenac 0.07%</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0b0c2372-bf11-4435-afb9-ac3b8abcbda1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_a157657e-50d4-4676-89d6-14e254d1c8eb"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_454c8dc4-b58e-4c24-b7b1-0d739af3a261"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Sulfite <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">Contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in non-<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> people.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_8e5200ab-8662-4ce5-bc3c-c1c11da63a3f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Slow or Delayed Healing</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_89acaac2-0567-4f21-a236-060040689e63"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Potential for Cross-Sensitivity</h2>
<p class="First">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_21574b27-1905-4b3e-a937-b0f7edcdfba3"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></h2>
<p class="First">With some NSAIDs, including bromfenac, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.</p>
<p>It is recommended that PROLENSA ophthalmic solution be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_39e917e3-55f9-4771-b65c-d62e06600480"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> and Corneal Reactions</h2>
<p class="First">Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health.</p>
<p>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</p>
<p>Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_1ddee7be-adb6-434f-a353-8a87c989e1cf"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Contact Lens Wear</h2>
<p class="First">PROLENSA should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of PROLENSA. The preservative in PROLENSA, benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_db59bf32-cf56-4aa6-a77a-b03479725664"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_f8f4952f-d803-45de-b71b-cb90bcd66db3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most commonly reported adverse reactions following use of PROLENSA following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery include: anterior chamber <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>. These reactions were reported in 3 to 8% of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_542f6143-aef0-47b9-b653-8385576f503a"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_4f2e2c5d-36fe-4350-81ce-7acfc5fb3e4d"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Treatment of rats at oral doses up to 0.9 mg/kg/day (systemic exposure 90 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and rabbits at oral doses up to 7.5 mg/kg/day (150 times the predicted human systemic exposure) produced no treatment-related malformations in reproduction studies. However, embryo-fetal lethality and maternal toxicity were produced in rats and rabbits at 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human exposure), and caused dystocia, increased neonatal mortality and reduced postnatal growth at 0.9 mg/kg/day.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of PROLENSA™ ophthalmic solution during late pregnancy should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7f0fd2fc-bbbc-4525-8237-0a9b75c4d179"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Caution should be exercised when PROLENSA ophthalmic solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_81c7a033-0a61-4a21-bd33-55bda627e7df"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy in pediatric patients below the age of 18 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_1cb2dfd2-67d5-4ccc-ae45-06bfec56eff6"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is no evidence that the efficacy or safety profiles for Prolensa differ in patients 70 years of age and older compared to younger adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_f0dff46b-4883-4864-941d-2a09b191a880"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">PROLENSA (bromfenac ophthalmic solution) 0.07% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.  Each mL of PROLENSA contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid).  The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium [2-amino-3-(4-bromobenzoyl) phenyl] acetate sesquihydrate, with an empirical formula of C<span class="Sub">15</span>H<span class="Sub">11</span>BrNNaO<span class="Sub">3</span>• 1½H<span class="Sub">2</span>O.  The chemical structure for bromfenac sodium sesquihydrate is:</p>
<div class="Figure">
<a name="id482"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4e072537-f73c-4a96-a65f-e2805ce112d8&amp;name=4e072537-f73c-4a96-a65f-e2805ce112d8-01.jpg">
</div>
<p>Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17.</p>
<p>PROLENSA ophthalmic solution is supplied as a sterile aqueous 0.07% solution, with a pH of 7.8. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of PROLENSA ophthalmic solution is approximately 300 mOsmol/kg.</p>
<p><span class="Bold">Each mL of PROLENSA ophthalmic solution contains:</span></p>
<p> <span class="Bold">Active</span>: Each mL contains bromfenac sodium sesquihydrate 0.0805%, which is equivalent to bromfenac free acid 0.07%</p>
<p><span class="Bold">Preservative</span>:  benzalkonium chloride 0.005%</p>
<p><span class="Bold">Inactives</span>:  boric acid, edetate disodium, povidone, sodium borate, sodium sulfite, tyloxapol, sodium hydroxide to adjust pH and water for injection, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_6f00264b-e16e-4881-baf9-94b45e075051"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_7fb5b0ae-0c4d-4e50-8f8e-af8ec105dd28"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_39556017-1a11-4961-9085-e412ea3c9a74"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The plasma concentration of bromfenac following ocular administration of 0.07% PROLENSA (bromfenac ophthalmic solution) in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_6f1353c6-0f6c-4055-9a26-1402a37ea250"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_de1baaa9-ae11-4693-8d94-43f2fdc4c5fc"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence.</p>
<p>Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.</p>
<p>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_c9e22549-a81d-410c-b70b-9ae0a114f1c0"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_duplicate_id_a034b30b-a445-4fb0-96ff-8c0b143475ac"></a><a name="section-11.1"></a><p></p>
<h2>14.1 Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></h2>
<p class="First">Bromfenac 0.07% QD for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and reduction of <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery.  Complete clearance of ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> by day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table.</p>
<table width="100%">
<col width="13%">
<col width="20%">
<col width="22%">
<col width="22%">
<col width="23%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="5"><p class="First">Proportion of Subjects with Cleared Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> (0 cells and no flare)</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study</p></td>
<td class="Botrule Rrule"><p class="First">Visit</p></td>
<td class="Botrule Rrule"><p class="First">Bromfenac 0.07%</p></td>
<td class="Botrule Rrule"><p class="First">Vehicle</p></td>
<td class="Botrule Rrule">
<p class="First">Difference (%)</p>
<p>(Asymptotic 95% CI)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 1</p></td>
<td class="Botrule Rrule"><p class="First">At Day 8</p></td>
<td class="Botrule Rrule"><p class="First">27/112 (24.1%)</p></td>
<td class="Botrule Rrule"><p class="First">7/108 (6.5%)</p></td>
<td class="Botrule Rrule"><p class="First">17.6 (8.4, 26.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">At Day 15</p></td>
<td class="Botrule Rrule"><p class="First">51/112 (45.5%)</p></td>
<td class="Botrule Rrule"><p class="First">14/108 (13.0%)</p></td>
<td class="Botrule Rrule"><p class="First">32.5 (21.4, 43.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2"><p class="First">Study 2</p></td>
<td class="Botrule Rrule"><p class="First">At Day 8</p></td>
<td class="Botrule Rrule"><p class="First">33/110 (30.0%)</p></td>
<td class="Botrule Rrule"><p class="First">14/110 (12.7%)</p></td>
<td class="Botrule Rrule"><p class="First">17.3 (6.7, 27.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">At Day 15</p></td>
<td class="Botrule Rrule"><p class="First">50/110 (45.5%)</p></td>
<td class="Botrule Rrule"><p class="First">30/110 (27.3%)</p></td>
<td class="Botrule Rrule"><p class="First">18.2 (5.7, 30.7)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">Proportion of Subjects who Were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Free</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study</p></td>
<td class="Botrule Rrule"><p class="First">Visit</p></td>
<td class="Botrule Rrule"><p class="First">Bromfenac 0.07%</p></td>
<td class="Botrule Rrule"><p class="First">Vehicle</p></td>
<td class="Botrule Rrule">
<p class="First">Difference (%)</p>
<p>(Asymptotic 95% CI)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Study 1</p></td>
<td class="Botrule Rrule"><p class="First">At Day 1</p></td>
<td class="Botrule Rrule"><p class="First">91/112 (81.3%)</p></td>
<td class="Botrule Rrule"><p class="First">47/108 (43.5%)</p></td>
<td class="Botrule Rrule"><p class="First">37.7 (25.9, 49.6)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Study 2</p></td>
<td class="Botrule Rrule"><p class="First">At Day 1</p></td>
<td class="Botrule Rrule"><p class="First">84/110 (76.4%)</p></td>
<td class="Botrule Rrule"><p class="First">61/110 (55.5%)</p></td>
<td class="Botrule Rrule"><p class="First">20.9 (8.7, 33.1)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b83e9b37-0c27-4bb7-99a9-464069bf1f5f"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PROLENSA (bromfenac ophthalmic solution) 0.07% is supplied in a white LDPE plastic squeeze bottle with a 15 mm LDPE white dropper-tip and 15 mm polypropylene gray cap as follows:</p>
<p>• 1.6 mL in a 7.5 mL container (NDC 24208-602-01)</p>
<p>• 3 mL in a 7.5 mL container (NDC 24208-602-03)</p>
<p><span class="Bold">Storage:</span> Store at 15º – 25ºC (59º – 77ºF).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_610059a7-8310-4b0d-8128-5ddf40670744"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_e03ac670-81ae-4ada-8f19-41baca5f091e"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Slowed or Delayed Healing</h2>
<p class="First">Advise patients of the possibility that slow or delayed healing may occur while using NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_7c96458d-2e80-4ab8-9499-042ee4dcde04"></a><a name="section-13.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</h2>
<p class="First">Advise patients to replace bottle cap after using and to not touch dropper tip to any surface, as this may contaminate the contents.</p>
<p>Advise patients that a single bottle of PROLENSA be used to treat only one eye.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_9fee1f38-1fba-4d13-acde-5c361d61b57a"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Concomitant Use of Contact Lenses</h2>
<p class="First">Advise patients to remove contact lenses prior to instillation of PROLENSA. The preservative in PROLENSA, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_f9316670-dadb-45f2-94fb-41668d01a642"></a><a name="section-13.4"></a><p></p>
<h2>17.4 Concomitant Topical Ocular Therapy</h2>
<p class="First">If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.</p>
<p>Manufactured by: Bausch &amp; Lomb Incorporated</p>
<p>Tampa, FL 33637</p>
<p>Under license from:</p>
<p>Senju Pharmaceuticals Co., Ltd.</p>
<p>Osaka, Japan 541-0046</p>
<p>®/™ are trademarks of Bausch &amp; Lomb Incorporated or its affiliates.</p>
<p>© Bausch &amp; Lomb Incorporated</p>
<p>9306700 (Flat)</p>
<p>9306800 (Folded)</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a2c0b7a7-2b85-4e65-ab18-0975f16d3419"></a><a name="section-14"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id686"></a><img alt="3 mL carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4e072537-f73c-4a96-a65f-e2805ce112d8&amp;name=4e072537-f73c-4a96-a65f-e2805ce112d8-02.jpg">
</div>
<p class="First">NDC 24208-602-03</p>
<p>Bausch &amp; Lomb</p>
<p>PROLENSA<span class="Sup">TM</span></p>
<p>(bromfenac ophthalmic solution) 0.07%</p>
<p>Sterile</p>
<p>Rx only</p>
<p>3 mL</p>
<p>Once Daily</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROLENSA 		
					</strong><br><span class="contentTableReg">bromfenac sodium solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-602</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BROMFENAC SODIUM</strong> (BROMFENAC) </td>
<td class="formItem">BROMFENAC</td>
<td class="formItem">0.7 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BORATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM SULFITE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TYLOXAPOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-602-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.6 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-602-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:24208-602-06</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">0.6 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203168</td>
<td class="formItem">04/08/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-602)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Regis Technologies Inc.</td>
<td class="formItem"></td>
<td class="formItem">005065594</td>
<td class="formItem">API MANUFACTURE(24208-602)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b018bfdc-44a1-4483-88a7-b3424733cf12</div>
<div>Set id: 4e072537-f73c-4a96-a65f-e2805ce112d8</div>
<div>Version: 7</div>
<div>Effective Time: 20130401</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
